Results 61 to 70 of about 344,680 (247)

A review of 74 patients with newly diagnosed multiple myeloma at a tertiary referral hospital in Nairobi, Kenya [PDF]

, 2014
Introduction: Multiple myeloma is a neoplastic disorder characterized by clonal proliferation of plasma cells. We aimed to carry out a retrospective audit to describe clinical and laboratory features of patients newly diagnosed with multiple myeloma ...
Etabale, Mbayah, Kiraka, G., Malkit, Riyat   +2 more
core   +1 more source

Ixazomib for relapsed or refractory multiple myeloma : review from an evidence review group on a NICE single technology appraisal [PDF]

, 2018
Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide plus dexamethasone (IXA-LEN-DEX) and licensed for relapsed or refractory multiple myeloma.
Armoiry, Xavier, Clarke, Aileen, Connock, M., Cummins, Ewen, Melendez-Torres, G. J., Royle, Pamela, Tsertsvadze, Alexander   +6 more
core   +1 more source

Multiple myeloma presenting with external ear canal mass [PDF]

, 2017
The manifestations of multiple myeloma are protean and related to bony osteolytic lesions, and to medullar and renal insufficiency. We report a patient who presented with otalgia as the inaugural symptom of multiple myeloma.
Abele, R., Allal, A. S., Dulguerov, P., Kurt, A.-M, Montandon, P., Quinodoz, D., Ruefenacht, D.   +6 more
core  

Advances in the design and development of oncolytic measles viruses. [PDF]

, 2015
A successful oncolytic virus is one that selectively propagates and destroys cancerous tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles virus (MV) is one such virus that exhibits this characteristic and thus has
Hutzen, Brian, Raffel, Corey, Studebaker, Adam W   +2 more
core   +1 more source

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma

HemaSphere
The 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptomatic multiple myeloma.
Anna deDaniel, Luis Gerardo Rodríguez‐Lobato, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Aina Oliver‐Caldés, Ignacio Isola, Ester Lozano, Joan Bladé, Laura Rosiñol, Carlos Fernández de Larrea   +10 more
doaj   +1 more source

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts [PDF]

, 2019
Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission.
Atkinson, Emily G., Bellido, Teresita, Delgado-Calle, Jesus, Galmarini, Carlos Maria, Kurihara, Noriyoshi, Miyagawa, Kazuaki, Nelson, Jessica, Roodman, G. David   +7 more
core   +1 more source

Myelomatous Pleural Effusion [PDF]

Multiple myeloma (MM) is a common hematologic malignancy. Pleural effusion is a rare presenting feature of multiple myeloma which carries a poor prognosis.
شیردل, عباس, عطاران, داود, غیاثی, تقی, قبادی مراللو, حسن   +3 more
core  

Increased plasma viscosity as a reason for inappropriate erythropoietin formation [PDF]

, 1993
The aim of this study was to examine whether altered plasma viscosity could contribute to the inappropriately low production rate of erythropoietin (EPO) observed in patients suffering from hypergammaglobulinemias associated with multiple myeloma or ...
Eckardt, Kai-Uwe, Götz, Karlheinz, Hamann, M., Kurtz, Armin, Ratcliffe, P. J., Reinhart, W. H., Singh, A., Zimmermann, A.   +7 more
core   +2 more sources

NKG2D and its ligands: one for all, all for one [PDF]

, 2018
The activating receptor NKG2D is peculiar in its capability to bind to numerous and highly diversified MHC class I-like self-molecules. These ligands are poorly expressed on normal cells but can be induced on damaged, transformed or infected cells, with ...
Cerboni, Cristina, Cippitelli, Marco, Fionda, Cinzia, Molfetta, Rosa, Paolini, Rossella, Santoni, Angela, Soriani, Alessandra, Zingoni, Alessandra   +7 more
core   +2 more sources

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects

Journal of Hematology & Oncology
Background Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral replication in the cancer cells was ...
Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci, Matt Coffey, Gerard Nuovo, Douglas W. Sborov, Flavia Pichiorri, Craig C Hofmeister   +20 more
doaj   +1 more source